Apotex Pays Out Over US Price-Fixing Claims
Deal Over Pravastatin Includes $24.1m Fine And Deferred Prosecution Agreement
Apotex has agreed to pay a $24.1m fine and enter into a deferred prosecution agreement to resolve US price-fixing claims over the cholesterol-lowering drug pravastatin.
You may also be interested in...
Amid media reports of Teva walking away from settlement negotiations with the US Department of Justice over generic price-fixing allegations, the Israeli company is officially maintaining silence over the matter.
Sandoz has agreed to pay a $195m criminal penalty, the largest for a US antitrust case, as part of a deferred prosecution agreement with the US Department of Justice to resolve antitrust allegations as part of the country’s ongoing investigation into generic price-fixing.
Former Taro executive Ara Aprahamian has been accused in the US of conspiracies covering generic price-fixing and allocation of customers, as well as for making false statements to investigating federal agents.